Lyell Immunopharma (LYEL) Operating Margin (2020 - 2026)
Lyell Immunopharma recorded quarterly Operating Margin of 2213050.0% in Q1 2026, down 4.03% quarter-over-quarter from 2127400.0% in Q4 2025, and down 139352143.0% year-over-year from N/an in Q1 2025.
Lyell Immunopharma's Operating Margin history runs 7 years deep, the most recent figure standing at 2213050.0% for Q1 2026.
- In Q1 2026, Operating Margin fell 139352143.0% year-over-year to 2213050.0%; the TTM figure through Mar 2026 stood at 826767.74% (down 27208005.0% YoY), while the FY2025 annual figure was 748344.44%, down 16022149.0% from the prior year.
- Operating Margin came in at 2213050.0% for Q1 2026 at Lyell Immunopharma, down from 2127400.0% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 30.55% in Q4 2022 to a low of 2214566.67% in Q3 2022.
- A 5-year average of 793232.29% and a median of 396369.23% in 2024 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin tumbled 221278224 bps in 2022 and jumped 197841067 bps in 2023, its largest moves.
- Lyell Immunopharma's Operating Margin stood at 30.55% in 2022, then tumbled by 1498065 bps to 457753.85% in 2023, then plunged by 299 bps to 1828609.09% in 2024, then fell by 16 bps to 2127400.0% in 2025, then declined by 4 bps to 2213050.0% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 2213050.0%, 2127400.0%, and 248353.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -2,213,050.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,213,050.00% |
| Dec 31, 2025 | -2,127,400.00% |
| Sep 30, 2025 | -248,353.33% |
| Jun 30, 2025 | -589,250.00% |
| Mar 31, 2025 | -819,528.57% |
| Dec 31, 2024 | -1,828,609.09% |
| Sep 30, 2024 | -148,544.12% |
| Jun 30, 2024 | -396,369.23% |
| Mar 31, 2024 | -1,852,500.00% |
| Dec 31, 2023 | -457,753.85% |
| Sep 30, 2023 | -236,156.00% |
| Jun 30, 2023 | -244,092.59% |
| Mar 31, 2023 | -96,240.00% |
| Dec 31, 2022 | -30.55% |
| Sep 30, 2022 | -2,214,566.67% |
| Jun 30, 2022 | -104.25% |
| Mar 31, 2022 | -12,400.72% |
| Dec 31, 2021 | -1,684.55% |
| Sep 30, 2021 | -1,784.43% |
| Jun 30, 2021 | -2,386.11% |
| Mar 31, 2021 | -2,264.62% |
| Dec 31, 2020 | -1,709.52% |
| Sep 30, 2020 | -3,443.27% |
| Jun 30, 2020 | -3,289.48% |